A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors

S
Shadia Jalal, MD

Primary Investigator

Overview

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Description

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    non small cell lung cancer,urothelial carcinoma,solid tumor,squamous cell carcinoma of the head and neck,brain metastasis
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic
Have adequate organ function
Have a performance status (PS) of less than or equal to on the Eastern Cooperative Oncology Group (ECOG) scale
Have discontinued previous treatments for cancer
Are able to swallow capsules
Exclusion Criteria
Currently enrolled in a clinical study
Have a serious concomitant systemic disorder
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C
Have a significant cardiac condition
Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor


Additional Information:
Participants will be compensated for their participation.

Updated on 09 Mar 2024. Study ID: 1708847726 (I9L-MC-JZCA)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center